Project Grant R03CA303915
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $178K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,458 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a digital intervention that uses patient portals to improve person-centered communication between cancer patients and oncology clinicians. The PERSON intervention comprises three automated, scalable components: a portal-enabled assessment tool (a 14-item questionnaire capturing patient information...
- The National Cancer Institute awarded New York University $310,185 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and feasibility-test a mobile application delivering an evidence-based intervention that addresses financial stress and smoking cessation. The recipient will develop a smartphone app version of the FIERCE (Financial Freedom from Cigarettes) intervention, which integrates financial coaching into smoking cessation treatment. The work...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The Sloan-Kettering Institute for Cancer Research was awarded a $923,999 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to conduct research on understanding the effects of tobacco smoking on African American patients with lung cancer. The award will support a multi-year research initiative from July 1, 2024 to June 30, 2027. As a non-profit organization focused on cancer research and patient care, Sloan-Kettering Institute for...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $709,145 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate senescence-modulating nanoparticles targeting P-selectin on senescent cells as a strategy to potentiate cancer immunotherapy in fibrotic tumors. The project addresses a barrier in cancer immunotherapy: many patients with solid tumors remain unresponsive to immune checkpoint blockade and CAR T cell...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $457,252 on June 10, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test RECONJOINT, a web-based preference elicitation tool for shared decision-making in breast reconstruction surgery. The award funds development of an implementation toolkit to support clinical integration of the RECONJOINT decision tool, which uses adaptive choice-based conjoint analysis to capture...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $366,662 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop statistical methodologies for mediation analysis using data from multiple incomplete sources in epidemiologic research. The project addresses a gap in current epidemiologic practice: existing mediation analysis methods require all three relevant variables (exposure, mediator, and outcome) to be present in a...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...